title: EFFECT OF PREGNANE XENOBIOTIC RECEPTOR ACTIVATION ON INFLAMMATORY BOWEL DISEASE TREATED WITH RIFAXIMIN.
abstract: The causes and pathogenesis of Inflammatory Bowel Disease (IBD) are still not clearly understood. This study aims to prove the important role of rifaximin played in inflammatory reaction caused by abnormity of the intestinal mucosal immune system. Intestinal microflora can greatly promote and maintain the inflammatory reaction of IBD, therefore, antibiotics can be used to treat IBD. Rifaximin is a medicine usually used for local intestinal infection. Many clinical and basic studies have shown that both a single application of rifaximin and the joint application with other medicines could achieve a good efficacy. This paper studied the activation of Pregnane Xenobiotic Receptor (PXR) in treating IBD with rifaximin and analyzed its efficacy in IBD when PXR was involved in the transport of medicine and metabolism. The results prove that rifaximin can not only serve as an anti-microbial drug, but can activate PXR and actually weaken the reaction of IBD. Thus it is safe to say that rifaximin has great potential in treating IBD.
authors.affiliation: Department of Endocrinology, China-Japan Union Hospital, Jilin University, Jilin University, Changchun, China.
authors.forename: Y C
authors.initials: YC
authors.lastname: Wan
authors.affiliation: Department of Anesthesiology, China-Japan Union Hospital, Jilin University, Jilin University, Changchun, China.
authors.forename: T
authors.initials: T
authors.lastname: Li
authors.affiliation: Department of Anesthesiology, China-Japan Union Hospital, Jilin University, Jilin University, Changchun, China.
authors.forename: Y-D
authors.initials: YD
authors.lastname: Han
authors.affiliation: Microscopic Examination Department, China-Japan Union Hospital, Jilin University, Changchun, China.
authors.forename: H-Y
authors.initials: HY
authors.lastname: Zhang
authors.affiliation: Department of Internal Medicine, Outpatient Department of Air Force Aviation University, Jilin University, Changchun, China.
authors.forename: H
authors.initials: H
authors.lastname: Lin
authors.affiliation: Microscopic Examination Department, China-Japan Union Hospital, Jilin University, Changchun, China.
authors.forename: B
authors.initials: B
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000473:pathology; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis / Q000235:genetics; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D016264:Dextran Sulfate / Q000633:toxicity; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000378:metabolism; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis / Q000235:genetics; D000077297:Pregnane X Receptor; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D011897:Random Allocation; D011987:Receptors, Steroid / Q000096:biosynthesis / Q000187:drug effects* / Q000235:genetics; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D012294:Rifamycins / Q000494:pharmacology / Q000627:therapeutic use*; D000078262:Rifaximin
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D016328:NF-kappa B; D009363:Neoplasm Proteins; D000077297:Pregnane X Receptor; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011987:Receptors, Steroid; D012294:Rifamycins; D016264:Dextran Sulfate; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D000078262:Rifaximin; D012293:Rifampin